Spots Global Cancer Trial Database for head and neck squamous cell carcinomas
Every month we try and update this database with for head and neck squamous cell carcinomas cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01) | NCT05724329 | Head and Neck S... | Tislelizumab + ... surgery Tislelizumab + ... | 50 Years - 80 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors | NCT05537740 | Advanced Solid ... | BAY3375968 Pembrolizumab | 18 Years - | Bayer | |
| Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I) | NCT05582265 | Head and Neck S... | Tislelizumab（ne... Cisplatin （neoa... Nab-paclitaxel ... Surgical resect... Cisplatin（adjuv... Tislelizumab（ad... Radiation Carboplatin (ne... Carboplatin (ad... | 18 Years - 80 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01) | NCT05724329 | Head and Neck S... | Tislelizumab + ... surgery Tislelizumab + ... | 50 Years - 80 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Myeloprotection With Trilaciclib in Pan-cancer Population | NCT06297811 | Non-Small Cell ... Breast Cancer Endometrial Can... Cervical Cancer Head And Neck S... | Trilaciclib Inj... Paclitaxel Carboplatin | 18 Years - | Sun Yat-sen University | |
| Myeloprotection With Trilaciclib in Pan-cancer Population | NCT06297811 | Non-Small Cell ... Breast Cancer Endometrial Can... Cervical Cancer Head And Neck S... | Trilaciclib Inj... Paclitaxel Carboplatin | 18 Years - | Sun Yat-sen University | |
| Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01) | NCT05724329 | Head and Neck S... | Tislelizumab + ... surgery Tislelizumab + ... | 50 Years - 80 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors | NCT05233436 | Advanced Solid ... Gastric Cancer Gastroesophagea... Urothelial Canc... Non Small Cell ... Head and Neck S... | PF-07265028 Sasanlimab | 18 Years - 99 Years | Pfizer | |
| Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer Treatment | NCT00935675 | Carcinomas | Escitalopram | 18 Years - 75 Years | Gustave Roussy, Cancer Campus, Grand Paris | |
| A Study of Toripalimab as Consolidation Therapy After Postoperative Chemoradiotherapy in HNSCC | NCT04992559 | Head and Neck S... | Consolidation T... | 18 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors | NCT05233436 | Advanced Solid ... Gastric Cancer Gastroesophagea... Urothelial Canc... Non Small Cell ... Head and Neck S... | PF-07265028 Sasanlimab | 18 Years - 99 Years | Pfizer | |
| A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors | NCT05537740 | Advanced Solid ... | BAY3375968 Pembrolizumab | 18 Years - | Bayer | |
| Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer Treatment | NCT00935675 | Carcinomas | Escitalopram | 18 Years - 75 Years | Gustave Roussy, Cancer Campus, Grand Paris |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
